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Abstract
Chronic obstructive pulmonary disease (COPD) is a common comorbidity of heart failure (HF), but remains often
undiagnosed, and we aimed to identify symptoms predicting COPD in HF. As part of an observational, prospective
study, we investigated stable smokers with a confirmed diagnosis of HF, using the 8-item COPD-Assessment-Test
(CAT) questionnaire to assess symptoms. All the items were correlated with the presence of COPD, and logistic
regression models were used to identify independent predictors. 96 HF patients were included, aged 74, 33% with
COPD. Patients with HF and COPD were more symptomatic, but only breathlessness when walking up a hill was an
independent predictor of COPD (odds ratio = 1.33, p = 0.0484). Interestingly, COPD-specific symptoms such as
cough and phlegm were not significant. Thus, in elderly smokers with stable HF, significant breathlessness when
walking up a hill is most indicative of associated COPD, and may indicate the need for further lung function
evaluation.
Background
The interaction between the lung and the heart is a com-
plex, vast, and fascinating subject, and from a clinical
point of view, disorders of the one often influence and
promote disorders of the other. This is especially true for
chronic diseases, with heart failure (HF) and chronic
obstructive pulmonary disease (COPD) representing a
common example: although prevalence rates vary across
published literature, it is estimated that about 17–35% of
patients with HF are affected by COPD [1]. Despite having
important diagnostic, prognostic, and therapeutic implica-
tions [2, 3], this disease seems to be rather underesti-
mated, and a significant rate of HF patients with
associated COPD remains undiagnosed and untreated [4].
It is known that the coexistence of these two disorders
poses different challenges to the treating physician (e.g.,
poor echocardiographic acoustic windows, putative
negative effects of bronchodilators, supposed limitation in
beta-blocker use) [5], but it should not be forgotten that
the first challenge is making a correct diagnosis in the
patient with HF and persistent dyspnea: is it because of
the heart or the lung?
In this regard, a careful assessment of symptoms is the
first approach for making a correct diagnosis (although
additional investigations such as spirometry are eventu-
ally required) [6]. The purpose of our study was to
evaluate the clinical presentation of stable smokers with
an establish diagnosis of HF, measuring their symptoms
with questionnaires and aiming to identify independent
clinical predictors of associated COPD. We had a prag-
matic approach, using quick and simple tools that could
easily be applied in everyday practice.
Methods
The present study is part of an observational, prospective,
3-year study conducted in a population of stable elderly
smokers[NCT01893918]. Subjects included in the present
investigation were consecutively enrolled while attending
regular follow up visits at a specialized outpatients clinic
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for HF, all being subjects with a diagnosis of HF confirmed
by a cardiologist team, including ischemic and
non-ischemic HF, as well as reduced and preserved
ejection fraction. To be evaluated for enrollment, the fol-
lowing criteria were required: aged ≥65 years; smoking
history of ≥20 pack/years; clinical stability. Exclusion cri-
teria included: other pulmonary conditions, cancer, acute
inflammatory diseases: new diagnosis of a major cardiac
comorbidity within the last 6 months; worsening of symp-
toms in the last 6 months; inability to comply with study
and/or informed consent. The study conformed to the
Declaration of Helsinki and was approved by the institu-
tional ethics committees. All participants provided in-
formed consent before recruitment.
After enrollment, all participants underwent several clin-
ical investigations, including recording of demographic
data, basic biochemistry, echocardiography, and screening
for COPD with symptom assessment and spirometry.
Spirometric diagnosis of COPD was confirmed according
to the postbronchodilator forced expiratory volume in the
1st second/forced vital capacity (FEV1/FVC) ratio < 0.7. [6]
Symptoms were evaluated in all patients using both the
modified Medical Research Council (mMRC) dyspnea scale
and the COPD-Assessment-Test (CAT), which have been
first developed for COPD, [7] and later used in patients
with concomitant COPD and HF [8, 9]. The mMRC grades
the level of dyspnea on a scale from 0 to 4, while the CAT
evaluates 8 different aspects of patient life (1-cough,
2-phlegm, 3-chest tightness, 4-breathlessness, 5-limitations
doing any activities at home, 6-confidence in leaving home,
7-sleep and 8-overall energy) grading each one on a 0–5
scale. For both tests, higher scores indicate worse symp-
toms. Finally, study investigators (including cardiologists
and pulmonologists) established a diagnosis of HF alone or
HF and COPD, based on all available study data.
For the current study, baseline symptom assessment
was correlated with the final diagnosis (HF alone vs. HF
and COPD). The mMRC and the CAT items were used
as standardized descriptors of patients’ symptoms,
providing a uniform and measurable assessment in all
patients. Descriptive statistics were used to compare
baseline characteristics between the two groups of HF or
HF and COPD, while univariate and multivariate logistic
regression models were used to search for independent
predictors of COPD. Analyses were performed by means
of R 3.3.2 statistical software (The R Foundation for
Statistical Computing).
Results
Study population included a total of 96 patients with HF,
of whom 32 (33%) had a final diagnosis of concurrent
COPD. Patients were mostly male, aged 74 ± 5.6, and
either current or former smokers with mean 39 ± 20 pack/
years. Left ventricle ejection fraction ranged 21 to 66%,
although on average was only mildly depressed (44% ± 10).
Not surprisingly, comorbidities were frequent, including
ischemic heart disease and diabetes. Overall, baseline
characteristics did not differ significantly between patients
with or without COPD (Table 1).
Enrolled HF patients were on average only mildly
symptomatic, with a mean mMRC of 1.3 ± 0.9 and CAT
of 9.9 ± 6.2. Both scores were significantly higher in pa-
tients with HF and COPD, as compared to HF alone
(1.7 ± 0.9 vs. 1.1 ± 0.9; p = 0.001, and 11.0 ± 6.0 vs. 9.4 ±
6.5;p < 0.001). Despite reaching statistical significance,
the absolute difference in mMRC was too small to find
clinical application, and further analysis was not
performed. On the contrary, each item of the CAT score
was evaluated singularly, with cough, phlegm, and
breathlessness being more frequent in patients with both
diseases. However, according to our multivariate logistic
regression model, after adjustment for sex, age and
smoke exposure, only item n.4 (breathlessness when
walking up a hill or one flight of stairs) maintained a lin-
ear correlation with the presence of COPD: for a 1-point
increase in the score, there was a relevant and statisti-
cally significant increased risk of being diagnosed with
concomitant COPD [odds ratio (OR) 1.33 (95% confi-
dence interval(CI) = 1.00–1.77; p = 0.048)], (Fig. 1).
Discussion
The results of our study could be summarized in a single,
practical indication: when evaluating a smoker, elderly
man with stable HF, ask her/him to grade her/his breath-
less when walking up a hill or one flight of stairs, from 0
(absent) to 5 (very breathless). Her/his answer will give a
simple and quick estimate of the risk of having concomi-
tant COPD, and in patients with high risk further testing
may be indicated. By contrast, and rather unexpectedly,
cough and sputum do not seem as helpful in suggesting
high risk of having concomitant COPD.
It is known that the identification of COPD in patients
with HF represents a challenge. Since the fundamental
symptom of one disease, i.e. dyspnea, is the leading
symptom also of the other, it is not uncommon to mis-
take one for the other. Thus, the rate of underdiagnosis
of COPD in HF may be as high as one every three pa-
tients [10]. Nevertheless, previous studies investigating
clinical characteristics of patients with established diag-
nosis of COPD and HF have reported significant differ-
ences, such as higher New York Heart Association class,
higher prevalence of dyspnea at rest, lower functional
status, and lower quality of life in patients with both
conditions [11, 12].
Thus, we believed that a pragmatic assessment of
symptoms in stable, elderly smokers with known HF
could provide a quick and useful first tool to evaluate
the risk of associated COPD, and therefore prompt
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Table 1 Characteristics of the population, overall and group-specific
Overall (n = 96) HF (n = 64) HF + COPD (n = 32) p*
Age – mean (SD) 74.14 (5.6) 74.14 (5.6) 74.13 (5.7) .99
Male (%) 91 89 94 .45
Pack/year – mean (SD) 39.1 (20.0) 39.0 (20.0) 39.4 (20.5) .93
BMI – mean (SD) 28.7 (4.3) 28.8 (3.7) 28.6 (5.3) .83
6MWT – mean (SD) 397 (160) 419 (155) 353 (164) .06
LVEF– mean (SD) 43.8 (10.0) 44.6 (10.0) 42.0 (10.2) .24
Hb – mean (SD) 13.6 (1.7) 13.6 (1.8) 13.6 (1.6) .98
GFR – mean (SD) 56.5 (20.1) 56.7 (19.9) 56.2 (20.8) .90
Comorbidities
CCI – mean (SD) 5.9 (1.7) 5.8 (1.6) 6.1 (1.8) .43
IHD (%) 65.6 67 62 .65
Stroke (%) 3.1 1.6 6.2 .21
CKD (%) 12.5 10.9 15.6 .51
PAD (%) 11.5 10.9 12.5 .82
Met synd (%) 67.7 71.9 59.4 .21
Diabetes (%) 34.4 39.1 25.0 .17
Osteoporosis (%) 2.1 1.6 3.1 .61
Anxiety (%) 4.2 1.6 9.4 .07
Symptoms
mMRC – mean (SD) 1.3 (0.95) 1.1 (0.92) 1.72 (0.9) .001
CAT – mean (SD) 9.9 (6.2) 9.4 (6.3) 11.0 (6.0) .001
*comparison between patients with HF and patients with HF + COPD
6MWT: 6-min walk test, BMI body mass index, CAT COPD assessment test, CCI Charlson comorbidity index, CKD chronic kidney disease, at least moderate, GFR
glomerular filtration rate, Hb hemoglobin, IHD ischemic heart disease, LVEF left ventricle ejection fraction; Met synd: metabolic syndrome, mMRC modified medical
research council, PAD peripheral artery disease
Fig. 1 Patient's probability of havig COPD according to each 1-point increase in CAT score
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further evaluation of lung function. By using a stan-
dardized questionnaire such as CAT, we could object-
ively measure symptoms in our population, and
highlight the most significant ones. According to our
result, higher grade of breathlessness is the best indica-
tor of concomitant COPD, which is in line with previ-
ous data. [13] As shown in Fig. 1, the probability to
find concomitant airway obstruction increases progres-
sively and linearly with increasing breathlessness, from
18.4 to 48.5%. Interestingly, symptoms such as cough
and phlegm were different between patients with HF
and patients with HF and COPD at univariate analysis,
but did not maintain a correlation at multivariate ana-
lysis. This is probably explained by the low prevalence
of cough and sputum in our population, suggesting that
these symptoms are indeed disease-specific, [14] but
are not frequently reported by stable patients. Thus, al-
though cough with or without phlegm is one of the
principal symptoms of COPD, [15] clinicians should
not rely only on it to suspect this lung disorders.
Our study presents some limitations, with the small
sample size being the major one. Moreover, the patients
were overall only mildly symptomatic, thus masking
potential differences among groups. Furthermore, there
were some baseline differences, such as higher prevalence
of anxiety in patients with both COPD and HF. Although
not being significantly different, and thus difficult to fur-
ther analyze, such differences may have influenced the
perception of breathlessness. Similarly, the use of a fixed
ratio for COPD, although recommended by the latest
GOLD document as the diagnostic criterion for airflow
limitation, [6] has been shown to overestimate the diagno-
sis in the elderly, which may have affected the results.
Therefore, interpretation of these data is not univocal and
definite conclusion cannot be drawn. Thus the study itself
should be regarded as hypothesis generating. Nevertheless,
being an observational study enrolling consecutive pa-
tients from a cardiologic clinic, our study is probably fairly
representative of everyday clinical practice. Additional
studies are needed to replicate our findings in a larger
population, and to evaluate their effective utility.
Conclusion
To conclude, in the era of technological medicine, these
data remind us of the importance of measuring patients’
symptoms. Grading breathlessness may point clinicians
in the right direction when evaluating stable, smoking
patients with HF, i.e. suspecting the presence of lung
impairment and help uncovering COPD. Our findings
remain mostly speculative and hypothesis-generating,
and future studies are needed to confirm these prelimin-
ary data, and to evaluate their cost-effectiveness in every-
day practice.
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